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Abstract: Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care 
aimed at maximizing the patient’s duration and quality of life. Treatment options for MBC have 
become more efficacious and numerous. In addition to endocrine and chemotherapy agents, 
a number of targeted agents, including trastuzumab and bevacizumab, have further enhanced 
the landscape of therapeutic options. Eribulin mesylate (E7389) is a nontaxane microtubule 
dynamics inhibitor, and a structurally simplified synthetic analog of the natural marine product, 
halichondrin B, with a novel mechanism of action that has shown antitumor activity in pretreated 
MBC. Eribulin has shown a manageable tolerability profile in Phase I–II clinical trials and an 
improvement in overall survival compared with treatment of physician’s choice, without relevant 
toxicities in a recently published Phase III trial. This review will focus on eribulin as a new 
active agent for MBC and its role in the management of breast disease.
Keywords: metastatic breast cancer, eribulin mesylate, halichondrin B, tubulin-targeted 
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Introduction
Breast cancer is the most frequently diagnosed cancer worldwide and is also the 
  second leading cause of death in women in the United States.1 The diagnosis of breast 
cancer metastases without a history of early-stage disease is rare, and approximately 
20% of patients with early breast cancer develop distant metastases within 5 years of 
the initial diagnosis.1,2 Despite improvements in the numerous chemotherapeutic agents 
that have been developed for the treatment of metastatic breast cancer (MBC), there is 
no standard of care for patients who have experienced failure with initial treatment.
Optimal treatment for patients with MBC is dependent upon the risks and benefits 
associated with each treatment option, as well as with the stage of disease and perfor-
mance status of each patient. Anthracyclines and taxanes are increasingly used as (neo)
adjuvant therapy, and therefore the number of patients previously exposed to these 
agents by the time they develop MBC is rising.3 Current chemotherapeutic options 
for third-line or later treatment of MBC include the vinca alkaloids,4,5 gemcitabine,6–8 
capecitabine,9–11 and ixabepilone,12–15 as well as new formulations of older drugs, such 
as liposomal anthracyclines16,17 and nanoparticle albumin-bound paclitaxel.18 Despite 
the large number of treatment options, the only approved monotherapies for late-line 
treatment of MBC are capecitabine and ixabepilone. Capecitabine has been approved 
in the United States and Europe for patients who are resistant to both taxane and 
anthracycline regimens, and for patients who experience taxane resistance or in whom 
anthracycline therapy is not indicated. On the other hand, ixabepilone is currently OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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approved in the United States for use in combination with 
capecitabine in patients who do not respond to anthracyclines 
and taxanes, or as a single agent for patients who have failed 
on anthracyclines, taxanes, and capecitabine.19–22
The management of MBC is complex due to the absence 
of clear evidence-based guidelines for clinicians and the 
large number of clinical studies developed with several 
compounds. Moreover, because consecutive diverse thera-
peutic regimens are administered, there is an increased risk 
of different cumulative toxicities and development of drug 
resistance, limiting the current treatment options available. 
Despite these risks, overall survival in patients with MBC is 
increasing, and many patients with MBC still benefit from 
three or more lines of treatment.23 Moreover, additional 
treatment options are needed for heavily pretreated MBC 
patients. Eribulin mesylate has emerged as a new option in 
the late-line setting. This review will focus on the current 
data for this new drug.
Antimicrotubule agents
Microtubules are polymers made from proteins called 
α- and β-tubulin and are part of the cytoskeleton within 
the cytoplasm of the cell. In addition to providing struc-
tural support, microtubules take part in many other cellular 
  processes.   During the early stages of mitosis, many micro-
tubules increase in length by attachment of more tubulin 
dimers to one end, and grow out from the spindle for long 
distances (10 µm) into the cell, searching for an unattached 
chromosome. If none is found, the microtubule loses dimers 
and shrinks again. This expansion and retraction is repeated 
many times until eventually it meets and becomes chemi-
cally attached to a chromosome. When every chromosome 
has been captured by a microtubule, they are collected into 
the correct order and are then separated into two halves to 
divide the cell in two parts.24,25 With this division, apoptosis 
is induced.
The central role of antimicrotubular agents in the treat-
ment of common epithelial cancers is further highlighted 
by their ability to induce remission in patients with classic 
drug-resistant epithelial cancers.26 Taxanes, vinca alkaloids, 
and epothilones are all microtubule-targeted agents which 
bind to tubulin with varying affinities and target different 
binding sites, with subsequent disruption of microtubule 
dynamics. This disruption occurs during mitosis with the 
induction of G2/M phase cell-cycle arrest that eventually 
leads to cell death by apoptosis.27,28 Among these agents, 
there are microtubule-stabilizing (paclitaxel,   nab-paclitaxel, 
docetaxel, and the epothilones, eg,   ixabepilone) and 
microtubule-  destabilizing drugs (vinca alkaloids, eg, 
  vincristine, vinblastine, and vinorelbine).29 However,   current 
microtubule-targeted treatment is often limited by the devel-
opment of drug resistance and common side effects,27,30 
frequently based on high incidences of chronic peripheral 
sensory and motor neuropathy, with some studies reporting 
up to 20%–30% for patients experiencing grade 3/4 neuro-
pathic symptoms.31 Other common adverse events which 
impact upon quality of life in patients who receive these 
treatments are neutropenia and fatigue, and often result in 
dose modification or discontinuation of treatment.31,32
Eribulin
Eribulin mesylate (E7389) is a structurally simplified syn-
thetic analog of the natural marine product, halichondrin 
B, a nontaxane microtubule dynamics inhibitor extracted 
from the marine sponge Halichondria okadai (Figures 1 
and 2) which inhibits structures called microtubules via 
a novel mechanism of action. Eribulin works by bind-
ing to microtubule polymerization, without affecting 
O
O
O
O
O
O
O
O
O
O
O O
O
O
O
O
H
H
HH
H H
HH
H
H
H H
H
H
HO
HO
HO
Figure 1 Molecular structure of halichondrin B.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
187
eribulin mesylate and metastatic breast cancer
depolymerization, and with the additional sequestration 
of tubulin into nonfunctional aggregates.33 By inhibiting 
mitotic spindle formation, eribulin causes irreversible 
mitotic block, which leads to cell cycle arrest in the G2/M 
phase and apoptosis.34,35 Moreover, eribulin binds to a 
limited number of high affinity sites at the plus ends of 
the microtubules, and there is some evidence against its 
binding to interdimer interfaces in pre-existing polymers. 
This property distinguishes eribulin mechanistically from 
other antimicrotubule agents, such as paclitaxel, ixabepi-
lone, and vinblastine.34,36,37
Eribulin, which retains the potency of halichondrin B 
against human cancer cell lines, has a mean terminal half-
life of 40 hours, and minimal renal excretion have been 
shown in preclinical studies.38 Although it has been noted 
that this compound is metabolized by cytochrome P450 
(CYP) 3A4, preclinical research established that it does 
not affect the metabolism of other therapeutic agents, such 
as diazepam, paclitaxel, midazolam, or tamoxifen, which 
are also metabolized by this system.39 Eribulin has shown 
antiproliferative effects against a broad range of human 
cancer cell lines, including breast, prostate, melanoma, and 
colorectal cancer,40 has been associated with tumor regres-
sion and elimination in a variety of well established human 
tumor xenograft models,41 and has demonstrated activity 
against paclitaxel-resistant cell lines, including those with 
mutations in β-tubulin.36,42
Based on its novel mechanism of action, which is distinct 
from that of other known classes of tubulin-targeted agents, 
and its encouraging preclinical activity, eribulin was selected 
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Figure 2 Molecular structure of eribulin. 
Table 1 Comparison between eribulin and other antimicrotubule 
agents active in MBC
Compound Mechanism of action Efficacy in MBC
Paclitaxel enhances polymerization  
of tubulin and interacts directly  
with microtubules, stabilizing  
them against depolymerization
RR, 40%–58% 
PFS, 9 months 
OS, 24 months
Docetaxel Promotes suppression of  
microtubule dynamics during  
the assembly and disassembly  
process
RR, 33% 
PFS, 5.3 months 
OS-
ixabepilone Binds to the αβ-tubulin  
heterodimer subunit and  
the rate of αβ-tubulin  
dissociation decreases, and  
has also been shown to induce  
tubulin polymerization into  
microtubules without the  
presence of GTP
RR, 11.5% 
PFS, 5.6 months 
OS, 8.6 months
vinorelbine inhibits mitosis at metaphase  
through its interaction with  
tubulin and interferes with:  
amino acid, cyclic AMP, and  
glutathione metabolism;  
calmodulin-dependent Ca2+  
transport ATPase activity;  
cellular respiration; and nucleic  
acid and lipid biosynthesis
RR, 28%–36% 
PFS, 4.1 months 
OS, 22.9 months
eribulin involves binding to a unique  
microtubule polymerization,  
without affecting  
depolymerization, and with  
additional sequestration of  
tubulin into nonfunctional  
aggregates
RR, 12% 
PFS, 3.7 months 
OS, 13.1 months
Abbreviations: OS, overall survival; PFS, progression-free survival; RR, response rate.
for evaluation in clinical trials. A comparison between   eribulin 
and other antimicrotubule inhibitors is made in Table 1.
Clinical efficacy and activity
Phase i trials
Four Phase I clinical trials have evaluated eribulin mesylate 
in various dose regimens in patients with different types of 
advanced solid tumors.38,43–45 Briefly, in the weekly regimen 
studies, the maximum tolerated dose of eribulin was reported to 
be 1.4 mg/m2 and 1 mg/m2. Eribulin was administered on days 1, 
8, and 15 of a 28-day cycle.44,45 On the other hand, a maximum 
tolerated dose of 2 mg/m2 was established on day 1 of a 21-day 
cycle schedule, and finally, dosing on days 1 and 8 of a 21-day 
cycle led to a maximum tolerated dose of 1.4 mg/m2.38,43 
Interestingly, some activity was observed in these trials. 
In the study by Goel et al, a partial response was observed 
in one patient (3.1%) and stable disease was observed in OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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10 patients (31.3%).44 Synold et al reported two partial 
responses (5.3%) and 12 patients (31.6%) experienced stable 
disease.45 In addition, 12 patients (57.1%) showed stable 
disease in the study reported by Tan et al,38 and Minami et al 
reported three patients with a partial response (20%) and four 
patients who achieved stable disease (26.7%).43
The most commonly reported dose-limiting toxicity 
in all four Phase I trials for eribulin was neutropenia. Two 
dose-limiting toxicities were reported at 2.0 mg/m2 (grade III 
febrile neutropenia in one patient, and grade IV neutropenia 
in another patient). Other serious nonhematologic toxicities 
included hypoglycemia, hypophosphatemia, and fatigue. In 
the study by Goel et al, grade III fatigue was observed in 
one patient at 0.5 mg/m2 which led to the expansion of that 
cohort. At 1.4 mg/m2, three patients developed grade III/
IV   neutropenia, which was considered to be a dose-limiting 
  toxicity based on the protocol criteria; febrile neutropenia 
developed in all three patients at 4.0 mg/m2, and two devel-
oped neutropenia at 2.8 mg/m2, which contributed to dose-
limiting toxicity at these different doses.44 In the study by 
Minami et al, dose-limiting grade IV neutropenia occurred in 
two of 15 patients (at 1.4 mg/m2 and 2.0 mg/m2, respectively), 
and grade III neutropenia occurred in four of 15 patients on 
the same dosing regimens.43
A further Phase IB combination study of eribulin 
and carboplatin in patients with advanced solid tumors 
determined the maximum tolerated dose of eribulin to be 
1.1 mg/m2 in combination with carboplatin (area under the 
curve 6 mg/dL/minute). The study reported a partial response 
in two patients (3.8%) and one complete response (1.9%).46 
Encouraging tumor response data from these four Phase I 
trials led to the initiation of Phase II studies in breast cancer 
patients, as well as in other types of solid tumors.
Phase ii trials
Three Phase II studies of eribulin in patients with advanced 
breast cancer or MBC have already been completed. Patients 
who participated in these trials had received extensive pre-
treatments with a median of three or four (range 1–11) prior 
chemotherapy regimens.47–49 The first study was published 
by Vahdat et al50 who investigated the efficacy and safety of 
eribulin in 87 evaluable patients with MBC who had received 
prior treatment with an anthracycline and taxanes. Based on 
the results of the previous Phase I study,45 eribulin   mesylate 
1.4 mg/m2 was initially administered as a 2–5-minute intrave-
nous infusion on days 1, 8, and 15 of a 28-day cycle. However, 
many patients experienced severe neutropenia on day 15 of 
the cycle (66% grade 3/4 in a 28-day cohort) and therefore 
the schedule was amended; eribulin mesylate was finally 
administered on days 1 and 8 of a 21-day cycle. In this study, 
eribulin demonstrated an objective response rate of 11.5% 
(95% confidence interval [CI], 5.7–20.1, all partial responses) 
and had a clinical benefit rate (partial response + stable disease 
for at least 6 months) of 17.2% (95% CI, 10.0–26.8).49 The 
median duration of response, median progression-free sur-
vival, and median overall survival were 171 days (5.6 months; 
range 1.4–11.9), 79 days (2.6 months; range 0.03–14.9), and 
275 days (9.0 months; range 0.5–27.2), respectively.49 The 
most common drug-related grade 3/4 toxicities were neutro-
penia (64%), leucopenia (18%), and fatigue (5%). 
In the second Phase II study, reported by Cortes et al, 
the patient population was based on 269 patients with 
locally advanced disease or MBC who had received prior 
treatment with anthracyclines, taxanes, and capecitabine. The 
patients received eribulin mesylate 1.4 mg/m2 as a 2–5-minute 
intravenous infusion on days 1 and 8 of a 21-day cycle. The 
primary endpoint of objective response rate by independent 
reviewer was 9.3% (95% CI, 6.1–13.4, all partial responses), 
the stable disease rate was 46.5%, and the clinical benefit 
rate (complete response + partial response + stable disease 
for at least 6 months) was 17.1%; the investigator-reported 
objective response rate for this study was 14.1% (95% CI, 
10.2–18.9). The median duration of response was 4.2 months, 
with median reported progression-free survival and overall 
survival times of 2.6 months and 10.4 months, respectively. 
The most common treatment-related grade 3/4 toxicities were 
neutropenia (54%), leucopenia (14%), and asthenia/fatigue 
(10%, no grade 4 reported). Grade 3 peripheral neuropathy 
occurred in 5.5% of patients (no grade 4 was reported).47
Finally, in the third Phase II trial, reported by Iwata 
et al,49 the safety and efficacy of eribulin was investigated in 
81 Japanese patients with advanced breast cancer who had 
previously been treated with an anthracycline and a taxane. 
This population study was less heavily pretreated than in 
the other two Phase II studies, with a median of only three 
prior treatments compared with four for the previously dis-
cussed two studies. The study implemented the same dosing 
regimen and mode of administration as that of the study by 
Cortés et al51 due to the schedule amendment needed in the 
study of Vahdat et al.50 The objective response rate by inde-
pendent reviewer was 21.3% (all partial responses; 95% CI, 
12.9–31.8) and the stable disease and clinical benefit rates 
were 37.5% and 27.5% (95% CI, 12.9–31.8), respectively. 
The median duration of response was 119 days (95% CI, 
85–148 days), the progression-free survival was 112 days 
(95% CI, 61–133 days), and overall survival was 331 days OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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(95% CI, 234, no upper limit determined due to shortage of 
events), respectively.48
In all three Phase II studies, eribulin showed a manageable 
tolerability profile, with most of the common drug-related 
adverse events being neutropenia, fatigue, alopecia, nau-
sea, and anemia (Table 2).47–49 Eribulin was also associated 
with a low incidence of peripheral neuropathy overall and 
severe peripheral neuropathy, which was limited to grade 3 
only.47–49
Phase iii trials
Following the encouraging pharmacokinetic and pharmacody-
namic results observed in the Phase I trials and the response 
rates without severe adverse events observed in the Phase II 
trials in patients with extensively pretreated locally advanced 
or MBC, a Phase III trial lead to the approval of eribulin in the 
United States for the treatment of MBC in patients who have 
received at least two previous chemotherapeutic regimens, 
including an anthracycline and a taxane. EMBRACE (Eisai 
Metastatic Breast Cancer Study Assessing Physician’s Choice 
Versus E7389) randomized patients with locally recurrent 
disease or MBC previously treated with 2–5 prior chemo-
therapy regimens (including anthracyclines and taxanes) to 
eribulin or treatment of physicians’ choice (TPC).50 Based 
on data obtained from the Phase II trials, eribulin mesylate 
was administered at a dose of 1.4 mg/m2 as a 2–5-minute 
intravenous infusion on days 1 and 8 of a 21-day cycle and 
compared with TPC, defined as a single-agent   chemotherapy, 
hormonal therapy, or biological therapy approved for the treat-
ment of cancer and administered according to local practice, 
radiotherapy, or symptomatic treatment alone. Treatment con-
tinued until disease progression, unacceptable toxic effects, a 
patient or physician request to discontinue, or serious protocol 
noncompliance. The primary endpoint of the study was to 
compare overall survival between the two treatment groups; 
  secondary objectives were to compare progression-free 
  survival, objective response rate, and   duration of response. 
Of the patients who received TPC (254 of a total of 762 
included in the study), 96% received chemotherapy and 4% 
received hormonal therapy, with no patients receiving biologi-
cal therapy or best supportive care. Baseline demographic 
characteristics were well balanced across the treatment groups, 
as shown in Table 3. Most of the patients included in the 
study were heavily pretreated with a median of four previ-
ous chemotherapy regimens. The median duration of eribulin 
treatment was 3.9 months, and 295 patients (59%) received 
five or more eribulin cycles. The study reached its primary 
objective, with a statistically significant increase in overall 
survival (hazard ratio 0.81; 95% CI, 0.66–0.99; P = 0.004) in 
the eribulin group (13.1 months) compared with TPC group 
(10.6 months).51 Median progression-free survival was 3.7 and 
2.2 months (hazard ratio 0.87; 95% CI, 0.71–1.05; P = 0.14), 
for the eribulin and TPC groups, respectively. The objective 
response rate was 12% in the eribulin group and 5% in the 
TPC group (P = 0.005). Finally, median duration of response 
for eribulin was 4.2 months (95% CI, 3.8–5.0) and for TPC 
was 6.7 months (95% CI, 6.7–7.0; P = 0.159). Adverse 
events occurred in 497 (99%) of 503 patients   receiving 
eribulin and 230 (93%) of 247 patients given TPC. Grade 3/4 
Table 2 Summary of most common grade 3/4 treatment-related 
adverse events from Phase ii studies of eribulin
Adverse event 
n (%)
Vahdat et al 
(n = 103)
Cortes et al 
(n = 291)
Total 
(n = 394)
Fatigue 5 (5)* 29 (10)* 34 (9)
Alopecia N/A N/A N/A
Neutropenia 66 (64) 157 (54) 223 (56.6)
Febrile neutropenia 4 (4) 19 (5.5) 20 (5.1)
Nausea 1 (1)* 6 (2.1)* 7 (1.7)
Anemia 1 (1)* 6 (2) 7 (1.7)
Note: *No grade 4. 
Abbreviation: N/A, not available.
Table 3 Patient baseline characteristics in eMBRACe
Eribulin % 
(n = 508)
TPC % 
(n = 254)
Total % 
(n = 762)
Median age (range) 55 (28–85) 56 (27–81) 55 (27–85)
eCOG performance status (%)
  0–1 
 2
91 
8
91 
9
91 
8
estrogen receptor- 
positive (%)
66 67 67
Progesterone receptor- 
positive (%)
50 48 50
HeR2 positive 16 16 16
Previous radiotherapy 83 77 81
Previous surgery 86 85 86
Number of organs involved
 # 2 
  .2
51 
49
46 
54
49 
51
Number of previous chemotherapy regimens
 # 3 
  .3 
  Median
49 
53 
4 (1–7)
45 
55 
4 (2–7)
48 
53 
4 (1–7)
Previous treatment
  Taxane 
  Capecitabine 
  Anthracycline
99 
73 
99
99 
74 
98
99 
73 
99
Refractory to Taxanes 
Capecitabine 
Anthracycline
81 
67 
56
80 
69 
61
81 
68 
58
Abbreviations: eCOG, eastern Cooperative Oncology Group; eMBRACe, eisai 
Metastatic Breast Cancer Study Assessing Physician’s Choice versus eribulin; HeR2, 
human epidermal growth factor receptor 2; TPC, treatment of physician’s choice.OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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adverse events associated with eribulin were asthenia/fatigue 
(8.2% grade 3; 0.6% grade 4), neutropenia, and peripheral 
neuropathy, demonstrating a manageable tolerability pro-
file for this agent when given as monotherapy51 (Table 4). 
  Globally, neutropenia was the most common clinical grade 
3 or 4 adverse event with eribulin (21.1% grade 3; 24.1% 
grade 4); neutropenia also occurred in the TPC subgroups 
treated with vinorelbine (30% grade 3; 10% grade 4), taxanes 
(13% grade 3; 16% grade 4), or gemcitabine (20% grade 3; 7% 
grade 4). It was managed with dose delays, dose reductions, 
and granulocyte colony-stimulating factor (given to 18% of 
patients in the eribulin group and 8% in the TPC group). The 
overall incidence of peripheral neuropathy on eribulin was 
35% (7.8% grade 3; 0.4% grade 4), and was similar to that 
observed in the taxane subgroup (45% overall, 5% grade 3, 
no grade 4). Moreover, it was the most common adverse event 
leading to discontinuation of eribulin in 5% of patients, but 
in those patients with grade 3 or 4 peripheral neuropathy who 
discontinued treatment, neuropathy improved to grade 2 or 
lower in later cycles after delays and dose reductions.50
Taken together, EMBRACE has shown a statistically 
significant improvement in its primary endpoint of overall 
survival by a median of 2.5 months with eribulin compared 
with TPC, and has also demonstrated a manageable tolerabil-
ity profile in patients with heavily pretreated MBC. This sur-
vival benefit for eribulin over standard therapy in this setting 
is remarkable and contrasts with the failure of other agents 
to improve overall survival when added to chemotherapy 
in other clinical trials. Moreover, the design of EMBRACE 
clearly reflects real practice, with the second arm of the study 
based on TPC as the comparator, the possibility of which 
allows choice of best therapy based on a combination of 
patient-related and tumor-related characteristics.
A second Phase III study is underway to compare the 
efficacy and safety of eribulin mesylate (1.4 mg/m2 as a 
2–5-minute intravenous infusion on days 1 and 8 of a 21-day 
cycle) with capecitabine. In this trial, 1100 patients have 
been randomized to receive eribulin or oral capecitabine on a 
2500 mg/m2/day schedule in two divided doses on days 1–14 
of a 21-day cycle.52 This study has two primary endpoints, 
ie, progression-free survival and overall survival, and in 
contrast with EMBRACE, it contains important quality of 
life and pharmacokinetic correlates. It will also use the same 
eribulin dosing schedule as EMBRACE and will also focus 
on those patients with disease progression despite receiving 
anthracyclines and taxanes. However, this study has more 
restrictive inclusion criteria and patients are not permitted 
to have received capecitabine for more than two previous 
chemotherapeutic regimens for MBC. The study has already 
finished recruitment and is currently investigating the effect of 
these drugs in combination in less extensively treated patients 
with locally advanced or MBC who have received up to three 
prior chemotherapy regimens, including anthracyclines and 
taxanes. Moreover, this will be the first study to provide a full 
analysis of the impact of eribulin upon quality of life.52
Conclusion
Eribulin is a novel nontaxane microtubule dynamics inhibi-
tor with a novel mechanism of action distinct from those of 
other tubulin-targeting agents. In Phase II and III trials, it 
has demonstrated therapeutic activity in patients with solid 
tumors, particularly in heavily pretreated patients with MBC. 
Moreover, in the Phase III EMBRACE study it was shown to 
prolong overall survival in heavily pretreated MBC patients 
who received eribulin as monotherapy with manageable toxic-
ity and a modest incidence of neuropathy, which appears to 
be lower than with other microtubule agents. Overall, eribulin 
represents a promising new treatment option for single-agent 
chemotherapy in patients with locally advanced disease or 
MBC previously treated with an anthracycline and a taxane.
Future perspectives
MBC is generally an incurable disease, with survival ranging 
from months to several years depending on tumor and patient 
characteristics. A wide range of treatment choices have been 
developed and are currently available, but most of them have 
not demonstrated an impact on survival in patients with MBC. 
Although currently there is no clear standard of care for these 
patients, important but modest improvements in overall sur-
vival have been observed for women with MBC. For women 
with endocrine-responsive disease, hormonal therapy is the 
appropriate initial treatment of choice at the time of disease 
recurrence. However, initiation of systemic chemotherapy is 
appropriate for women with metastatic disease that is either 
hormone receptor-negative, refractory to endocrine therapy, 
Table 4 Main grade 3/4 toxicities of eribulin in eMBRACe
Grade 3 Grade 4
Hematological toxicity (%)
  Neutropenia 
  Leukopenia 
  Anemia 
  Febrile neutropenia
21.1 
11.7 
1.8 
3.0
41.1 
2.2 
0.2 
1.2
Fatigue 8.2 0.6
Peripheral neuropathy 7.8 0.4
Dyspnea 3.6 0
Abbreviation:  eMBRACe,  eisai  Metastatic  Breast  Cancer  Study  Assessing 
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or rapidly progressive, with important visceral involvement 
regardless of hormonal status.53 The addition of an anti-HER2 
agent to chemotherapy for women with HER2-positive breast 
cancer represents a clear standard of care for this population, 
with an impact on survival in this group of patients.54 Eribulin 
represents a new option for patients with heavily pretreated 
MBC and, due to the results of the clinical trials, it is likely to be 
partnered with other chemotherapy agents, anti-HER2 agents, 
and other drugs targeting important biologic pathways.
Eribulin has also demonstrated efficacy in heavily pre-
treated patients with MBC and a statistically significant 
improvement in survival in this group of patients. This 
encouraging efficacy, coupled with a manageable tolerabil-
ity profile, has led to its approval by the US Food and Drug 
Administration and the European Agency for the Evaluation 
of Medicinal Products for the treatment of MBC in patients 
who have previously received chemotherapy including an 
anthracycline and a taxane. In addition, there are clinical 
trials underway to assess the antitumor activity of eribulin in 
the preoperative setting and also the earlier use of eribulin in 
the course of metastatic disease. It is hoped that these stud-
ies will translate the important survival advantage seen in 
the heavily pretreated refractory setting of the EMBRACE 
study into corresponding benefits for those patients with 
early-stage breast cancer. Moreover, a randomized Phase II 
study is comparing neuropathy associated with eribulin and 
with ixabepilone,55 and there are other ongoing studies of 
eribulin in multiple types of solid tumors, with some data 
showing activity in urothelial cancer, prostate cancer, and 
sarcoma.
In summary, eribulin is the only drug that has shown a 
survival advantage in late lines of therapy for patients with 
metastatic breast cancer. The benefit that eribulin has shown 
as a single agent in this setting suggests that this drug could 
become a new standard of care for these patients. Future 
studies should explore whether survival with late lines of 
therapy are indicative of a more effective drug used earlier 
and in the (neo)adjuvant setting, and should look to establish 
the optimal use of eribulin.
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